|Day Low/High||31.97 / 32.04|
|52 Wk Low/High||10.26 / 32.12|
Both pharma companies are promising names that easily could become buyout targets.
The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...
The sector seems to be rebounding after tumbling by more than 40%.
The market continues to trade lower as we late morning, with Tobira Therapeutics serving as the "disaster du jour" in the small-cap biotech space. This stock is trading down some 60% after its midstage compound targeting non-alcoholic steatohepatiti...
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Shares of Relypsa surged on news of a takeover by Galenica, the owner of Switzerland's biggest pharmacy network.
General Motors crushed Wall Street earnings estimates before the opening bell.
Updates on smaller housing, retail and biotech plays recently mentioned on these pages.
These mid-caps would do well by themselves, but could tempt bigger companies.
Also, Thermo Fisher annouces an acquisition as takeover talks boost Valeant shares.
Good morning! Bret Jensen here! It's good to be standing in for Doug Kass on Doug's Daily Dairy this Friday, especially on a day when my "Best Idea" Relypsa (RLYP) is likely to soar. After the bell Thursday, the U.S. Food and Drug Administration ess...
FDA decision will impact Relypsa's buyout potential while Aritana won't stay this undervalued.
It is hard to see much growth in the market overall, until earnings growth returns.
After an asset price drop, large pharmaceutical companies are looking for strategic purchases.
These concerns are well on their way to FDA approval for their first commercialized products in addressable markets.
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
The market is off to a good start, as the futures had portended earlier. Industrial and construction stocks seem to be doing particularly well. Rail-car maker Greenbrier Cos. (GBX) continues to show strength even after a recent earnings report that ...
Good morning -- Bret Jensen here! As always, it's good to be standing in for Doug Kass. It looks like the rollercoaster in the market will continue today. We had a nice rally on Wednesday, followed by a deep decline yesterday. And this morning, the ...